A Randomized, Double-blind, Placebo-controlled Cross-over Study to Determine the Bronchodilator Effect of a Single Dose of Fluticasone Furoate (FF)/ Vilanterol (VI) 100/25 mcg Combination Administered in the Morning in Adult Patients With Asthma
Phase of Trial: Phase I
Latest Information Update: 12 May 2017
At a glance
- Drugs Vilanterol/fluticasone furoate (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 01 Oct 2016 Primary endpoint (Change from baseline in FEV1 at 15, 30 minutes, 1, 2, 4, 12, 24, 36, 48, 60 and 72 hours post dose.) has been met, accordign to the article published in Respiratory Medicine.
- 01 Oct 2016 Results published in the Respiratory Medicine.
- 14 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.